Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $64.35 million. The enterprise value is $123.40 million.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 7.80 million shares outstanding. The number of shares has increased by 27.43% in one year.
| Current Share Class | 7.80M |
| Shares Outstanding | 7.80M |
| Shares Change (YoY) | +27.43% |
| Shares Change (QoQ) | +2.28% |
| Owned by Insiders (%) | 52.01% |
| Owned by Institutions (%) | 13.63% |
| Float | 3.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.79 |
| Forward PS | 0.65 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.84
| Current Ratio | 1.84 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.37 |
Financial Efficiency
Return on equity (ROE) is -302.55% and return on invested capital (ROIC) is -24.95%.
| Return on Equity (ROE) | -302.55% |
| Return on Assets (ROA) | -21.12% |
| Return on Invested Capital (ROIC) | -24.95% |
| Return on Capital Employed (ROCE) | -45.84% |
| Revenue Per Employee | $293,674 |
| Profits Per Employee | -$144,821 |
| Employee Count | 273 |
| Asset Turnover | 0.84 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.06% in the last 52 weeks. The beta is 0.64, so Biodesix's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -69.06% |
| 50-Day Moving Average | 7.60 |
| 200-Day Moving Average | 10.10 |
| Relative Strength Index (RSI) | 63.36 |
| Average Volume (20 Days) | 305,383 |
Short Selling Information
The latest short interest is 97,662, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 97,662 |
| Short Previous Month | 161,558 |
| Short % of Shares Out | 1.25% |
| Short % of Float | 3.02% |
| Short Ratio (days to cover) | 1.12 |
Income Statement
In the last 12 months, Biodesix had revenue of $80.17 million and -$39.54 million in losses. Loss per share was -$5.36.
| Revenue | 80.17M |
| Gross Profit | 63.99M |
| Operating Income | -32.35M |
| Pretax Income | -39.54M |
| Net Income | -39.54M |
| EBITDA | -26.61M |
| EBIT | -32.35M |
| Loss Per Share | -$5.36 |
Full Income StatementBalance Sheet
The company has $16.60 million in cash and $72.93 million in debt, giving a net cash position of -$56.32 million or -$7.22 per share.
| Cash & Cash Equivalents | 16.60M |
| Total Debt | 72.93M |
| Net Cash | -56.32M |
| Net Cash Per Share | -$7.22 |
| Equity (Book Value) | -1.72M |
| Book Value Per Share | -0.22 |
| Working Capital | 15.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.15 million and capital expenditures -$1.01 million, giving a free cash flow of -$29.16 million.
| Operating Cash Flow | -28.15M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -29.16M |
| FCF Per Share | -$3.74 |
Full Cash Flow StatementMargins
Gross margin is 79.82%, with operating and profit margins of -40.35% and -49.31%.
| Gross Margin | 79.82% |
| Operating Margin | -40.35% |
| Pretax Margin | -49.31% |
| Profit Margin | -49.31% |
| EBITDA Margin | -33.20% |
| EBIT Margin | -40.35% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.43% |
| Shareholder Yield | -27.43% |
| Earnings Yield | -58.94% |
| FCF Yield | -43.47% |
Analyst Forecast
The average price target for Biodesix is $32.50, which is 293.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.50 |
| Price Target Difference | 293.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
